ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 023

Effect of Type 1 Interferons and JAK Inhibitors on Gene Expression in Bioengineered Pediatric Skeletal Muscle

Lauren Covert1, Joseph Prinz2, Hailee Patel3, Jeffrey Dvergsten4 and George Truskey3, 1Duke University, Durham, NC, 2Duke University School of Medicine, Department of Biostatistics and Bioinformatics, Durham, NC, 3Duke University, Department of Biomedical Engineering, Durham, NC, 4Duke University Hospital, Durham, NC

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: dermatomyositis, genetics, interferon, Muscle Biology, Tissue Engineering

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Thursday, March 30, 2023

Title: Poster Breakout 3 - Pediatric Rheumatology Potpourri

Session Type: Breakout Session

Session Time: 5:10PM-5:40PM

Background/Purpose: Genetic studies of new-onset juvenile dermatomyositis (JDM) exhibit elevation of Type 1 interferons (IFN 1) IFNα and IFNβ in blood, skin, and muscle. To understand the relationship of IFN 1 to muscle dysfunction we used an in vitro 3D biomimetic construct derived from healthy pediatric muscle (myobundles). IFN 1 reduces myobundle contractile force, upregulates MHC class 1 and induces donor-specific expression of myositis-specific antigens. Janus kinase inhibitors (JAKi) have therapeutic effect in Type 1 interferonopathies. In this study we evaluated gene expression of myobundles exposed to IFNα or β as well as after cotreatment with IFNβ and JAKi, tofacitinib or baricitinib.

Methods: Myoblasts isolated from 3 healthy pediatric donors were cultured and used to create donor-specific myobundles, exposed to 0 (control), 5, 10 or 20 ng/mL IFNα or β. In a separate protocol myobundles were exposed to 0 (control) or 20 ng/mL IFNβ for a total of 10 days then treated with tofacitinib 1 µM or baricitinib 500 nM from days 3-10 of IFNβ exposure. Myobundle mRNA was isolated for sequencing. Quality profiling and alignment of mRNA was performed using the fastp toolkit and splice aware STAR RNA-seq alignment tool, respectively. Differential expression was performed using the DESeq2 Bioconductor package. Independent filtering was used prior to calculating adjusted p-values, and moderated log2 fold-changes were derived using the ashr package. Gene set enrichment analysis was performed using hallmark pathways associated with altered gene expression for each comparison performed.

Results: Eighty-three myobundles from 3 healthy pediatric donors were analyzed. PCA analysis indicates distinct clusters of similar gene expression across IFNα-exposed and IFNβ-exposed myobundles vs. untreated controls, respectively (Figure 1). IFNβ-exposed myobundles treated with JAKi have gene profiles more similar to controls. The top 5 most overexpressed and downregulated genes after exposure to 20 ng/mL IFNα or IFNβ vs. control are listed in Table 1 and included interferon response genes and proinflammatory genes. Gene Set Enrichment Analysis showed that IFNα induced enrichment of 29/50 pathways (58%) with IFNβ enrichment of 33/50 pathways (66%). Key enriched pathways included IFNα and γ response genes and inflammatory response genes. IFNα downregulated oxidative phosphorylation genes while IFNβ decreased expression of myogenesis genes (Figure 2). Treatment with IFNβ and JAKi had significantly less pathway enrichment (baricitinib with 13/50 and tofacitinib 16/50 enriched) with key enriched pathways involving skeletal muscle myogenesis.

Conclusion: IFNα and IFNβ have distinct effects on pediatric skeletal muscle gene expression, with upregulation of IFN and inflammatory response genes and downregulation of oxidative phosphorylation and myogenesis genes. Genetic profiles are significantly altered by JAKi, baricitinib and tofacitinib. Results demonstrate the potential of bioengineered pediatric skeletal muscle to advance our knowledge of JDM pathogenesis and provide a platform for investigating promising therapeutics.

Supporting image 1Figure 1. PCA plot of all myobundle samples. Green arrows show shift after IFNα; black arrows show greater shift in PC1 after IFNβ.

Supporting image 2Table 1. Most overexpressed and downregulated genes after IFN 1 exposure in pediatric skeletal myobundles. lncRNA = long non-coding RNA; IRG = interferon response gene

Supporting image 3Figure 2. GSEA pathways after IFN I exposure


Disclosures: L. Covert: None; J. Prinz: None; H. Patel: None; J. Dvergsten: None; G. Truskey: None.

To cite this abstract in AMA style:

Covert L, Prinz J, Patel H, Dvergsten J, Truskey G. Effect of Type 1 Interferons and JAK Inhibitors on Gene Expression in Bioengineered Pediatric Skeletal Muscle [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/effect-of-type-1-interferons-and-jak-inhibitors-on-gene-expression-in-bioengineered-pediatric-skeletal-muscle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-type-1-interferons-and-jak-inhibitors-on-gene-expression-in-bioengineered-pediatric-skeletal-muscle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology